RxDoctor Payments Data

Michael Avery, DO

Rheumatology · Green Bay, WINPI 1255568069

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.2% of the total across 185 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 66.6% of it on its own, with 16 other manufacturers making up the rest.

$2,347in general payments, 2019–2025

Across 185 payments — averaging $12.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$192
  • Novartis$109
  • Genentech USA, Inc.$85
  • Lilly USA, LLC$81
  • GSK$65
  • plus $251 from 11 others

What the payments were for

  • Food & beverage$2,32799%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie142$1,564
Amgen(2 entities)12$192
Novartis6$109
Genentech USA, Inc.4$85
Lilly USA, LLC4$81
GSK4$65
AstraZeneca2$44
Johnson & Johnson2$36
TG Therapeutics, Inc.1$28
E.r. Squibb & Sons, L.L.C.1$27
Octapharma USA, Inc.1$24
Sobi, Inc1$19
Sandoz1$19
Abbott1$18
US Oncology Corporate, Inc.1$17
Lundbeck LLC1$14
Electronic Waveform Lab, Inc.1$6

How this compares

$2,347 in reported general payments places this provider in the 70th percentile of 120 rheumatology providers in Wisconsin.

See all rheumatology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$1,656,526
Medicare patients
479
Services billed
83,860

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab137$1,129,063
Enbrel SureclickEtanercept96$775,896
Xeljanz XrTofacitinib Citrate56$323,832
EnbrelEtanercept40$301,113
Actemra ActpenTocilizumab35$178,183
Cimzia (2 Pack)Certolizumab Pegol31$173,328
Enbrel MiniEtanercept12$87,788
OtezlaApremilast17$78,672
Hydroxychloroquine Sulfate1,296$51,165
MethotrexateMethotrexate Sodium824$22,704
Colchicine138$10,921
OtrexupMethotrexate/Pf13$9,214
Leflunomide147$8,078
Prednisone833$5,110
Atovaquone12$4,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel, Otezla$192$379,78457 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 120 rheumatology providers in Wisconsin.

Other rheumatology in Green Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →